Scientific posters being presented at SLAS and AGBT highlight key advantages of AI-enabled Deepcell REM-I Platform as a tool for advancing our understanding of cells
MENLO PARK, Calif.–February 1, 2024– Deepcell, a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced upcoming poster presentations at the Society for Laboratory Automation and Screening (SLAS) meeting in Boston, Massachusetts, from February 3-7, 2024, and at the Advances in Genome Biology and Technology (AGBT) general meeting in Orlando, Florida, from February 5-8, 2024. In addition, the company announced that its REM-I Platform is a finalist for the New Product Award at SLAS.
“We look forward to sharing the tremendous progress we’ve made as a company with the scientific community at these meetings. A year ago, we were presenting our first public datasets at AGBT and attending SLAS for the first time. This year, we have the REM-I Platform in field testing, are presenting substantially more data, and look forward to the full commercialization of our instrument later this year,” said Maddison Masaeli, Ph.D., co-founder and chief executive officer at Deepcell. “Following our first presentation at the J.P. Morgan Healthcare conference last month, where we laid out our vision for our AI-enabled cell morphology technology and announced a groundbreaking collaboration with NVIDIA to advance the use of generative AI in cell biology, we remain committed to pushing the boundaries of cell biology and identifying more ways to unveil the unseen while reimagining biology.”
SLAS Poster Presentation Details
Title: Determination of cell viability using high-dimensional morphology analysis
Poster number: 1259-D
Date and Time: Tuesday, February 6, 2024 2:00–3:00 p.m. ET
ABGT Poster Presentation Details
Title: Determination of cell viability using high-dimensional morphology analysis
Poster Number: 548
Date and Time: Tuesday, February 6, 1:30-3:30 p.m. ET
Title: Integrating deep learning- driven morphology profiling, cell sorting, and single cell RNASeq reveals sample diversity and enriched sub-populations
Poster Number: 590
Date and Time: Tuesday, February 6, 1:30-3:30 p.m. ET
Title: Self-supervised deep learning enables label-free high dimensional morphology profiling of immune cell subtypes
Poster Number: 628
Date and Time: Tuesday, February 6, 1:30-3:30 p.m. ET
Title: Morphology profiling driven by deep learning characterizes functional changes in CRISPR knockout cell lines
Poster Number: 605
Date and Time: Wednesday, February 7, 4:45-6:10 p.m. ET
Title: Self-supervised foundation model captures high dimensional morphology data from single cell brightfield images
Poster Number: 629
Date and Time: Wednesday, February 7, 4:45-6:10 p.m. ET
To learn more about Deepcell and the REM-I Platform, visit us in booth #876 at SLAS, in villa 4105 at AGBT, or at deepcell.com.
About Deepcell
Deepcell is a life science company which brings artificial intelligence to cell biology, unlocking a new field of high-dimensional biological discovery known as morpholomics. Through Deepcell’s AI-powered imaging and microfluidics solution, the REM-I Platform, the company is enabling a new scale of cell biology research and single cell analysis leveraging cellular morphology for unbounded discovery. Deepcell’s platform leverages its artificial intelligence model, the Human Foundation Model, to identify and sort cells based on morphological distinctions helping power basic and translational research and offering future applications in diagnostic testing and therapeutics targeting. The company was spun out of Stanford University in 2017 and has raised nearly $100 million in venture capital. It is based in Menlo Park, California. Learn more at www.deepcell.com or follow us on LinkedIn, Twitter, and YouTube.
Media Contact
Gwen Gordon
Gwen@gwengordonpr.com
